TITLE

6-THIOGUANINE IS WELL TOLERATED AND REASONABLY EFFECTIVE IN CROHN'S DISEASE PATIENTS WHO ARE RESISTANT OR INTOLERANT OF AZATHIOPRINE AND METHOTREXATE

PUB. DATE
April 2004
SOURCE
Gut;Apr2004 Supplement 3, Vol. 53, pA104
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The management of patients with Cohen's disease (CD) who have failed to respond or are intolerant to azathioprine and methotrexate remains challenging. Red blood cell 6-thioguaninenucleotide levels correlate with drug efficacy and bone marrow suppression in patients treated with azathioprine. 6-thioguanine forms 6-TON more. In the short term, 6-TG is well tolerated and con be an effective alternative in CD patients who are resistant or intolerant to azathioprine and methotrexate. Recent reports of abnormal liver function with nodular hyperplasia are of concern but were not confirmed in this study over 6 months of treatment.
ACCESSION #
13219221

 

Related Articles

  • Immunomodulation does not alter histology in resected Crohn’s disease. Frizelle, F. A.; Ing, A.; Gearry, R. B.; Whitehead, M.; Faragher, I. G.; Dobbs, B. // Techniques in Coloproctology;Dec2009, Vol. 13 Issue 4, p295 

    The use of immunomodulators (Azathioprine, 6-Mercaptopurine and Methotrexate) and biological agents (Infliximab and adalimumab) for the treatment of Crohn’s disease (CD) has increased in the recent years with the aim of treating the inflammatory component of the disease and hoping to...

  • Infliximab in Takayasu arteritis: a safe alternative? Karageorgaki, Zaharenia Th.; Mavragani, Clio P.; Papathanasiou, Matthilde A.; Skopouli, Fotini N. // Clinical Rheumatology;Jun2007, Vol. 26 Issue 6, p984 

    To test the efficacy of Infliximab, a chimeric monoclonal antibody against TNF-α, in the treatment of Takayasu arteritis. We used infliximab at an initial dose of 3 mg/kg i.v. at weeks 0, 2, 6, and 8 thereafter in combination with methotrexate or azathioprine, to treat four patients with...

  • Cytotoxic and Immunologic Effects of Methotrexate in Psoriasis. Weinstein, Gerald D.; Jeffes, Edward; McCullough, Jerry L. // Journal of Investigative Dermatology;Nov90, Vol. 95 Issue 5, p49S 

    Based on recent experience that Cyclosporin A, an immunosuppressive drug, produces marked improvement in psoriasis, possible immunomodulatory activities of methotrexate (MTX) have been reviewed to look for alternate mechanisms of MTX action in psoriasis. It is generally considered that the...

  • Adalimumab.  // Reactions Weekly;7/9/2011, Issue 1359, p6 

    The article describes two cases of women with Crohn's disease who developed mural aortic thrombosis while undergoing adalimumab therapy.

  • Adalimumab.  // Reactions Weekly;7/9/2011, Issue 1359, p6 

    The article describes the case of a 54-year-old woman with Crohn's disease who developed vitiligo while receiving treatment with adalimumab.

  • New pathophysiological insights and modern treatment of IBD. Engel, Matthias A.; Neurath, Markus F. // Journal of Gastroenterology;Jun2010, Vol. 45 Issue 6, p571 

    Inflammatory bowel disease (IBD), which comprises two main types, namely, Crohn’s disease and ulcerative colitis, affects approximately 3.6 million people in the USA and Europe, and an alarming rise in low-incidence areas, such as Asia, is currently being observed. In the last decade,...

  • Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Vermeire, Severine; Noman, Maja; Van Assche, Gert; Baert, Filip; D'Haens, Geert; Rutgeerts, Paul // Gut;Sep2007, Vol. 56 Issue 9, p1226 

    Background: Episodic infliximab (IFX) treatment is associated with the formation of antibodies to IFX (ATIs) in the majority of patients, which can lead to infusion reactions and a shorter duration of response. Concomitant use of immunosuppressives (IS) reduces the risk of ATI formation. Aims...

  • Understanding the Use of Immunosuppressive Agents in the Clinical Management of IBD. Waters, O. R.; Lawrance, I. C. // Current Drug Targets;Aug2011, Vol. 12 Issue 9, p1364 

    No abstract available.

  • How fast up the ladder? Factors associated with immunosuppressive or anti-TNF therapies in IBD patients at early stages: results from a population-based cohort. Ott, Claudia; Takses, Angela; Obermeier, Florian; Schnoy, Elisabeth; Salzberger, Bernd; Müller, Martina // International Journal of Colorectal Disease;Nov2014, Vol. 29 Issue 11, p1329 

    Background: With the introduction of anti-TNF therapies in the treatment of IBD, the therapeutic strategies have changed to an accelerated step-up care to avoid long-term complications. Little is known about the implementation of these strategies into daily care. We aimed to evaluate this...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics